Arrowhead Pharmaceuticals Inc (ARWR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Arrowhead Pharmaceuticals Inc stock (ARWR) is currently trading at $60.77. Arrowhead Pharmaceuticals Inc PE ratio is 37.98. Arrowhead Pharmaceuticals Inc PS ratio (Price-to-Sales) is 7.80. Analyst consensus price target for ARWR is $81.36. WallStSmart rates ARWR as Hold.
- ARWR PE ratio analysis and historical PE chart
- ARWR PS ratio (Price-to-Sales) history and trend
- ARWR intrinsic value — DCF, Graham Number, EPV models
- ARWR stock price prediction 2025 2026 2027 2028 2029 2030
- ARWR fair value vs current price
- ARWR insider transactions and insider buying
- Is ARWR undervalued or overvalued?
- Arrowhead Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ARWR Piotroski F-Score and Altman Z-Score
- ARWR analyst price target and Smart Rating
Arrowhead Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
ARWR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Arrowhead Pharmaceuticals Inc (ARWR)
ARWR trades 71% above its Graham fair value of $35.97, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Arrowhead Pharmaceuticals Inc (ARWR) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, revenue growth, profit margin. Concerns around peg ratio and price/book. Fundamentals are solid but monitor weak areas for improvement.
Arrowhead Pharmaceuticals Inc (ARWR) Key Strengths (5)
Every $100 of shareholder equity generates $76 in profit
Revenue surging 10461.00% year-over-year
84.41% of shares held by major funds and institutions
Strong profitability: $19 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Arrowhead Pharmaceuticals Inc (ARWR) Areas to Watch (5)
PEG ratio is negative or unavailable
Very expensive at 13.9x book value
Premium valuation at 7.8x annual revenue
Modest earnings growth at 9.80%
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
Arrowhead Pharmaceuticals Inc (ARWR) Detailed Analysis Report
Overall Assessment
This company scores 58/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 3.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Institutional Own.. Profitability is solid with Return on Equity at 75.50%, Profit Margin at 18.50%. Growth metrics are encouraging with Revenue Growth at 10461.00%.
The Bear Case
The primary concerns are PEG Ratio, Price/Book, Price/Sales. Some valuation metrics including PEG Ratio (N/A), Price/Sales (7.80), Price/Book (13.87) suggest expensive pricing. Growth concerns include EPS Growth at 9.80%, which may limit upside. Profitability pressure is visible in Operating Margin at 15.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 75.50% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 10461.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Revenue Growth) and negatives (PEG Ratio, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARWR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARWR's Price-to-Sales ratio of 7.80x trades at a deep discount to its historical average of 1749.98x (3th percentile). The current valuation is 100% below its historical high of 9378.37x set in Feb 2014, and 10% above its historical low of 7.07x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Arrowhead Pharmaceuticals Inc (ARWR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Arrowhead Pharmaceuticals Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.1B with 10461% growth year-over-year. Profit margins of 18.5% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 10461% YoY, reaching 1.1B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 7550.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Arrowhead Pharmaceuticals Inc maintain 10461%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Arrowhead Pharmaceuticals Inc.
Bottom Line
Arrowhead Pharmaceuticals Inc offers an attractive blend of growth (10461% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Arrowhead Pharmaceuticals Inc(ARWR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.